New start-up company, Gyros AB, completes move to Swedish center of biotechnology and begins expansion.
New start-up company, Gyros AB, completes move to Swedish center of biotechnology and begins expansion. The new biotech company, Gyros AB, has moved to new offices and laboratory facilities in Uppsala Science Park, Sweden in connection with the expansion of the company's R & D, marketing and sales organizations. Gyros AB announced today the completion of its move to Uppsala Science Park, Sweden after its spin off from Amersham Pharmacia Biotech, a leading supplier to the life science market. Gyros AB offers pharmaceutical, biotechnology and diagnostic companies access to a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into client-specific CDs. Thousands of analyses can be performed in parallel on each disposable microlaboratory. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. 'Our initial contacts with pharmaceutical and diagnostic clients have been extremely positive' said Maris Hartmanis, President and CEO of Gyros AB 'They have seen immediately the advantages offered by such a unique technology platform.' The proprietary technology of Gyros AB has been under development at Amersham Pharmacia Biotech over the previous decade. During this period a significant patent portfolio, now owned by Gyros, has been established. 'We are now in a process of rapid expansion' said Per Sjöberg, Vice President Commercial Operations at Gyros AB, 'Interest from clients throughout the world has convinced us that now is the time to present this novel technology to the market place.' Gyros AB shareholders include the Swedish investors The National Pension Insurance Fund (Sixth Fund Board), Investor Growth Capital, Karolinska Investment Fund, the Swedish Union of Clerical and Technical Employees in Industry, HealthCap, the Danish investor BankInvest and Amersham Pharmacia Biotech. About Gyros AB Gyros AB offers the pharmaceutical, biotechnology and diagnostic companies access to a unique, proprietary technology platform in which routine or non-routine laboratory processes can be miniaturized and integrated into client-specific CDs. Thousands of analyses can be performed in parallel on each disposable microlaboratory. This new platform brings outstanding gains in efficiency, cost-effectiveness and information content. The ability to integrate different laboratory steps on a single CD offers the potential to reassess and redesign traditional working procedures. The company was founded in 2000 and has its offices based in the Science Park in Uppsala, Sweden. For further information, visit www.gyrosmicro.com or contact: Maris Hartmanis, President and CEO, Gyros AB Tel: +46 (0)18 566 330 Mobile: +46 (0)70 562 8617 Email: maris.hartmanis@gyrosmicro.com Per Sjöberg, Vice President Commercial Operations, Gyros AB Tel: +46 (0)18 566 318 Mobile: +46 (0)70 5444799 Email: per.sjoberg@gyrosmicro.com Media information (financial) Maris Hartmanis, President and CEO, Gyros AB Tel: +46 (0)18 566 330 Mobile: +46 (0)70 562 8617 Email: maris.hartmanis@gyrosmicro.com Media information (trade): Sue Cresswell, Marketing Communications Tel: +46 (0)8 54472620 Mobile: +46 (0)705 519520 Email: sue.cresswell@gyrosmicro.com Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards. ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/12/19/20001214BIT01490/bit0001.doc http://www.bit.se/bitonline/2000/12/19/20001214BIT01490/bit0002.pdf